Meeting Reports:
Results and prospects of development of new polyphenolic drugs for cancer patients
PDF | HTML | How to cite
Metrics: PDF 1272 views | HTML 1802 views | ?
Abstract
Vladimir N. Anisimov1, Stig Larsen2, Stig Lofberg3, Irina A. Baldueva1, Anastasia V. Malek1,4, Tea Kirkegaard Nielsen3,5, Elena I. Fedoros6,1, Irina V. Perminova7, Evgeny Yu. Drobyshev1,8, Vladimir N. Bykov9, Andrey V. Panchenko1, Alexander M. Scherbakov1 and Alexey M. Belyaev1
1 N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russia
2 Norwegian University of Life Sciences, Oslo, Norway
3 Meabco AS, Copenhagen, Denmark
4 Oncosystema LTD, Moscow, Russia
5 University of Copenhagen, Copenhagen, Denmark
6 Nobel LTD, Saint-Petersburg, Russia
7 M.V. Lomonosov Moscow State University, Moscow, Russia
8 Institute of Toxicology, Federal Medical-Biological Agency, Saint-Petersburg, Russia
9 S.M. Kirov Military Medical Academy, Saint-Petersburg, Russia
Correspondence to:
Vladimir N. Anisimov, email:
Keywords: cancer, breast cancer, clinical trial, polyphenols, cancer chemotherapy
Received: October 20, 2017 Accepted: October 25, 2017 Published: November 07, 2017
Abstract
The conference “Results and prospects of development of new polyphenolic drugs for cancer patients” took place at the N.N. Petrov National Medical Research Center of Oncology (PNMRCO) on May 31, 2017, and gathered researchers involved in development and evaluation of medicinal products based on the novel lignin-derived soluble polyphenolic polymer BP-Cx-1. BP-Cx-1 is the platform for a portfolio of innovative pharmacological products such as BP-C1, BP-C2 and BP-C3.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22307